Related Experiment Video
Updated: Dec 27, 2025
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
18.7K
Somatostatin Analogs in Clinical Practice: a Review
Mariana Gomes-Porras1, Jersy Cárdenas-Salas2, Cristina Álvarez-Escolá1
1Department of Endocrinology, "La Paz" University Hospital. Paseo de la Castellana, 261, 28046 Madrid, Spain.
International Journal of Molecular Sciences
|March 4, 2020
Summary
Somatostatin analogs are effective treatments for various tumors, including neuroendocrine and endocrine types. They also show promise in managing digestive diseases and certain non-endocrine cancers.
Area of Science:
- Endocrinology
- Oncology
- Gastroenterology
Background:
- Somatostatin analogs are crucial for managing specific pituitary and neuroendocrine tumors.
- Dopamine agonist-resistant pituitary tumors may benefit from somatostatin analog therapy.
Purpose of the Study:
- To review the broad therapeutic applications of somatostatin analogs.
- To highlight their efficacy in endocrine, non-endocrine, and digestive diseases.
Main Methods:
- Literature review of somatostatin analog applications.
- Analysis of therapeutic outcomes across diverse medical conditions.
Main Results:
- Established efficacy in treating somatotropinomas, thyrotropinomas, and gastroenteropancreatic neuroendocrine tumors.
- Demonstrated effectiveness as an alternative for resistant pituitary adenomas.
- Shown utility in managing congenital hyperinsulinism, diabetic complications, and various non-endocrine tumors.
- Proven beneficial for chronic refractory diarrhea, gastrointestinal bleeding, and other digestive disorders.
Conclusions:
- Somatostatin analogs are versatile therapeutic agents with a wide range of applications.
- Their safety and efficacy support their use beyond initial indications in endocrine oncology and gastroenterology.
Keywords:
Somatostatin analogcancercarcinoidlanreotideneuroendocrine tumoroctreotidepasireotidepituitary adenomaMore Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
761
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
761
01:06Oral Hypoglycemic Agents: Glinides
510
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
510
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
534
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
534
01:17Oral Hypoglycemic Agents: Sulfonylureas
666
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
666
01:23Dipeptidyl Peptidase 4 Inhibitors
491
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
491
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
471
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
471